Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic ^{18}F-FDG PET/CT

Ron Epelbaum[1], Alex Frenkel[2], Riad Haddad[3], Natalia Sikorski[4], Ludwig G. Strauss[5], Ora Israel[2], and Antonia Dimitrakopoulou-Strauss[5]

[1]Department of Oncology, Rambam Health Care Campus and Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; [2]Department of Nuclear Medicine, Rambam Health Care Campus and Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; [3]Department of Surgery, Carmel Medical Center, Haifa, Israel; [4]Department of Oncology, Lin Medical Center, Haifa, Israel; and [5]Medical PET Group-Biological Imaging, Clinical Cooperative Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

This study aimed to assess the role of a quantitative dynamic PET model in pancreatic cancer as a potential index of tumor aggressiveness and predictor of survival. **Methods:** Seventy-one patients with ^{18}F-FDG–avid adenocarcinoma of the pancreas before treatment were recruited, including 27 with localized tumors (11 underwent pancreatectomy, and 16 had localized nonresectable tumors) and 44 with metastatic disease. Dynamic ^{18}F-FDG PET images were acquired over a 60-min period, followed by a whole-body PET/CT study. Quantitative data measurements were based on a 2-compartment model, and the following variables were calculated: VB (fractional blood volume in target area), K_1 and k_2 (kinetic membrane transport parameters), k_3 and k_4 (intracellular ^{18}F-FDG phosphorylation and dephosphorylation parameters, respectively), and ^{18}F-FDG INF (global ^{18}F-FDG influx). **Results:** The single significant variable for overall survival (OS) in patients with localized disease was ^{18}F-FDG INF. Patients with a high ^{18}F-FDG INF (>0.033 min^{-1}) had a median OS of 6 and 5 mo for nonresectable and resected tumors, respectively, versus 15 and 19 mo for a low ^{18}F-FDG INF in nonresectable and resected tumors, respectively ($P < 0.04$). In metastatic disease, multivariate analysis found VB, K_1, and k_3 to be significant variables for OS ($P < 0.043$, <0.031, and <0.009, respectively). Prognostic factors for OS in the entire group of patients that were significant at multivariate analysis were stage of disease, VB, K_1, and ^{18}F-FDG INF ($P < 0.00035$, <0.03, <0.024, and <0.008, respectively). Median OS for all patients with a high ^{18}F-FDG INF, low VB, and high K_1 was 3 mo, as opposed to 14 mo in patients with a low ^{18}F-FDG INF, high VB, and low K_1 ($P < 0.021$), irrespective of stage and resectability. **Conclusion:** Quantitative ^{18}F-FDG kinetic parameters measured by dynamic PET in newly diagnosed pancreatic cancer correlated with the aggressiveness of disease. The ^{18}F-FDG INF was the single most significant variable for OS in patients with localized disease, whether resectable or not.

Key Words: dynamic ^{18}F-FDG PET; ^{18}F-FDG influx; pancreatic cancer; survival

Pancreatic cancer (PC) is the tenth most common malignancy and the fourth leading cause of cancer death in the United States, with 1- and 5-y survival rates of 26% and 6%, respectively, for all stages combined and of only 23% at 5 y in patients with local disease. At presentation, less than 20% of patients are candidates for surgery, with the remainder having either locally advanced nonresectable or metastatic disease (1).

Patients with the same stage of PC exhibit variable clinical behavior. Although most patients with early-stage disease amenable to pancreatectomy will have further locoregional or metastatic failure, 20% of them will enjoy long-term survival. Histopathologic factors including tumors larger than 2 cm, moderate to poor histology grade, positive resection margins, and lymph node involvement are associated with shorter survival (2). Defining the aggressiveness of PC before surgery is a clinical challenge. If this challenge can be met, it may enable identification of subgroups of resectable tumors with different prognoses and prediction of the need for and efficacy of surgery and neoadjuvant or adjuvant therapy. Locally advanced nonresectable PC can show rapid progression during treatment or, alternatively, a response sufficient to warrant exploration and resection of the tumor. Furthermore, a small subgroup of patients with metastatic PC has been reported to have prolonged survival after treatment with gemcitabine (3). These differences in response and survival provide evidence for the heterogeneity of PC and for the clinical importance of accurate risk stratification and subsequent tailored treatment in patients with advanced disease as well.

^{18}F-FDG PET/CT has an established role in the work-up of various malignancies. The metabolic activity of a tumor, expressed by the degree of ^{18}F-FDG uptake, is assessed using visual parameters of presence, size, and intensity of tracer uptake or using semiquantitative measurements of the standardized uptake value (SUV), prone, however, to variability (4).

Uptake of ^{18}F-FDG is the result of a dynamic process. A dynamic ^{18}F-FDG PET protocol for quantitative analysis using kinetic modeling has been previously described (5–11).

These studies have assessed the value of kinetic PET parameters in the differential diagnosis of benign versus malignant lesions and for evaluating response to treatment and survival in colorectal carcinoma, soft-tissue sarcomas, and multiple myeloma (6–10).

The working hypothesis of the current study assumes that ^{18}F-FDG kinetics quantitation may define tumor aggressiveness and predict prognosis in clinically heterogeneous malignancies such as PC, with a potential impact on individual treatment tailoring. The present study aimed to assess whether dynamic ^{18}F-FDG PET/CT parameters can be used as prognostic tools in PC.

MATERIALS AND METHODS

Study Population

Seventy-one patients with adenocarcinoma of the pancreas who had not yet been treated were recruited between September 2006 and April 2009 (Table 1). There were 40 men and 31 women, with a median age of 68 y (range, 39–79 y). Twenty-seven patients had localized disease, including 11 patients who underwent pancreatectomy (followed by adjuvant chemotherapy and chemoradiation in 1 patient each, whereas 9 patients were followed up only), and 16 patients had locally advanced non-resectable PC (14 received gemcitabine-based chemotherapy, with radiation therapy added in 7). Forty-four patients had disseminated disease, 5 with single and 39 with 2 or more metastases, and were treated with single-agent gemcitabine or with gemcitabine and cisplatin in combination.

The study was approved by the institutional ethical (Helsinki) committee. All patients signed an informed consent form.

Imaging Protocol

Patients fasted for 4 h before the administration of ^{18}F-FDG except for glucose-free hydration. Dynamic PET was started with the intravenous administration of 370–555 MBq of ^{18}F-FDG for a single field of view (FOV) over the upper abdomen to include the pancreas for a total acquisition time of 60 min, including a 28-frame series acquired at 4 intervals: 10×30 s/frame, 5×60 s/frame, 5×120 s/frame, and 8×300 s/frame.

After the completion of this research protocol, oral contrast material was administered. A whole-body PET/CT acquisition study started 2 h after radiotracer injection using the routine protocol including 5–7 FOVs and 4 min/FOV, for a total acquisition time of 20–28 min.

The study was performed using a PET/CT device (Discovery LS; GE Healthcare) starting with a CT acquisition, followed by a PET study of the same axial range. PET images were reconstructed using ordered-subset expectation maximization software, with CT attenuation correction. PET, CT, and fused PET/CT images were reviewed in axial, coronal, and sagittal planes on the Xeleris workstation (GE Healthcare).

Dynamic PET data analysis was performed using the PMOD software package (PMOD Technologies Ltd.).

Data Processing and Analysis

For the quantitative evaluation, irregular volumes of interest (VOIs) consisting of several regions of interest were drawn manually in target areas over the tumor and over a large artery within the FOV. Parametric tumor images were calculated on the dynamic PET data, fitting a linear regression function to time–activity data for each voxel (11). Tracer kinetics were assessed using the standard 2-tissue-compartment model methodology (12). The accurate input function measurement, which theoretically requires arterial blood sampling, is retrieved with this protocol, from the mean arterial VOI values with previously demonstrated good accuracy (13). The arterial VOI consisted of at least 7 ROIs defined on sequential PET images. The descending aorta was preferentially used because it can be easily defined on the dynamic image sequence and because of low spill-over from other organs. A preprocessing PMOD tool allowed a fit of the input curve by a sum of up to 3 decaying exponentials to reduce the noise that could otherwise affect parameter estimates.

The transport constant K_1 and rate constants k_2, k_3, and k_4 were calculated using a 2-compartment model implemented in PMOD considering the vascular fraction (VB) in a VOI as an additional variable (11). The model parameters were accepted when VB was between 0 and 1 and K_1–k_4 were less than 1 (as required by the model convergence). Rate constants K_1–k_4 are expressed in 1/min. VB reflects the fraction of blood within the evaluated volume. After compartment analysis, the global influx of ^{18}F-FDG (^{18}F-FDG INF) was calculated from the compartment data as $(K_1 \times k_3)/(k_2 + k_3)$.

A noncompartment model based on the fractal dimension (FD) was also used. FD is a parameter of heterogeneity and was calculated for the time–activity data in each individual voxel of a VOI. FD values vary between 0 and 2, representing the deterministic or chaotic tracer activity distribution (14).

Whole-body ^{18}F-FDG PET/CT was analyzed visually by an experienced nuclear medicine physician with knowledge of the patient's clinical history and the report of previously performed CT. Areas of focal increased ^{18}F-FDG activity that could not be assigned to physiologic radiotracer distribution or benign processes were defined as malignant. ^{18}F-FDG avidity in the primary pancreatic tumor and metastases was recorded as ^{18}F-FDG–positive or ^{18}F-FDG–negative. Semiquantitative maximum SUV assessment of the intensity of ^{18}F-FDG uptake was measured twice: on the last frame of the dynamic study (SUV_1) and on the whole-body study (SUV_2)

TABLE 1
Clinical Characteristics of 71 Patients with PC

Characteristic	No. of patients
Stage	
Resectable	11
Locally advanced nonresectable	16
Metastatic	44
Treatment	
Resectable tumor	
Surgery	9
Surgery + chemotherapy	1
Surgery + chemoradiation	1
Locally advanced nonresectable	
Chemoradiation	7
Chemotherapy	7
Palliative care	2
Metastatic	
Chemotherapy	44

Median age of patients was 68 y, and age range was 39–79 y.

measured 2 h after injection, using the same region of interest surrounding the tracer-avid tumor.

Statistical Analysis

The relationship between kinetic parameters, clinical and histo-pathologic risk factors, and overall survival (OS) was assessed for the whole group with PC and for subgroups with localized and metastatic disease.

Univariate analysis was performed for the following variables: for the whole study group—patient age, tumor stage, location in pancreas, and differentiation; for patients with localized disease who underwent pancreatectomy—tumor size, margins, lymph node status, and adjuvant therapy; and for patients with metastatic disease—extension to one or more sites of malignancy. PET-related variables included VB, K_1, k_2, k_3, k_4, ^{18}F-FDG INF from the compartmental analysis, FD from the fractal dimension analysis, SUV_1, and SUV_2.

Multivariate Cox proportional hazards regression analysis was performed only on variables with a P value of less than 0.2 on univariate analysis. The significant variables on multivariate analysis were plotted on Kaplan–Meyer curves with a cutoff value established by receiver-operating-characteristic analysis as a discriminator. The statistical analysis of survival curves used the log rank test, and statistical evaluation was performed using the MedCalc (MedCalc) and GraphPad software (GraphPad Inc.).

RESULTS

Univariate survival analysis of clinical–pathologic and kinetic PET parameters in the study group is shown in Tables 2 and 3, and multivariate analysis of the significant variables is shown in Table 4.

Localized PC

Median OS for 27 patients with localized disease was 14 mo, with no difference between resected and nonresectable disease. Prognosticators of OS by univariate analysis, to be included in the multivariate analysis, were VB, K_1, FD, ^{18}F-FDG INF, and SUV_2. Multivariate analysis found ^{18}F-FDG INF as the only significant variable for OS ($P < 0.0092$). Patients with a high and low ^{18}F-FDG INF (above and below 0.033, respectively) had a median OS of 6 and 19 mo, respectively ($P < 0.033$; Fig. 1).

In 11 patients who underwent pancreatectomy, univariate analysis found lymph node status, adjuvant therapy, VB, K_1, k_2, FD, ^{18}F-FDG INF, SUV_1, and SUV_2 as prognosticators of OS, and these parameters were further included in the multivariate analysis. Multivariate analysis found ^{18}F-FDG INF as the only significant variable for OS ($P < 0.046$). Patients with a high ($n = 5$) and low ($n = 6$) ^{18}F-FDG INF (above and below the value of 0.026, respectively) had a median OS of 6 and 19 mo, respectively ($P < 0.032$).

In 16 patients with locally advanced unresectable disease, univariate analysis prognosticators for OS included tumor location, FD, and ^{18}F-FDG INF. Multivariate analysis found tumor location and ^{18}F-FDG INF to be significant variables for OS ($P = 0.019$ and 0.016, respectively). Patients with a high and low ^{18}F-FDG INF (above and below the value of 0.042, respectively) had a median OS of 6 and 15 mo, respectively ($P < 0.005$). Median OS was 13 and 2 mo in patients with tumor in the pancreatic head and other locations, respectively ($P < 0.04$).

For the whole group with localized disease, the ^{18}F-FDG INF cutoff value of 0.033 predicted a median OS of 5, 6, 15, and 19 mo for patients with resected high ^{18}F-FDG INF, nonresectable high ^{18}F-FDG INF, nonresectable low ^{18}F-FDG INF, and resected low ^{18}F-FDG INF, respectively ($P < 0.041$; Fig. 2). Examples of the relationship between OS and ^{18}F-FDG tumor uptake kinetic curves used for the calculation of ^{18}F-FDG INF are displayed in Figure 3.

Metastatic PC

The median OS of 44 patients with metastatic disease was 5 mo. Univariate analysis prognosticators of OS ($P < 0.2$), further included in the multivariate analysis, were VB, K_1, k_2, k_3, and ^{18}F-FDG INF. Multivariate analysis found VB, K_1, and k_3 to be significant variables for OS ($P < 0.043$, <0.031, and <0.009, respectively). The median OS was 5 and 7 mo in patients with VB below and above the value of 0.071 ($P < 0.05$), 4 and 6 mo for K_1 above and below 0.35 ($P < 0.02$), and 4 and 8 mo for k_3 above and below 0.041 ($P < 0.02$), respectively.

TABLE 2
Univariate Survival Analysis of Clinical and Pathologic Parameters

| Variable | All patients ($n = 71$) | Localized | | | Metastatic ($n = 44$) |
		All ($n = 27$)	Resected ($n = 11$)	Nonresectable ($n = 16$)	
Age	$P < 0.83$	$P < 0.83$	$P < 0.38$	$P < 0.80$	$P < 0.37$
Stage	$P < 0.001^*$				
Tumor location	$P < 0.31$	$P < 0.75$	$P < 0.51$	$P < 0.04^*$	$P < 0.85$
Tumor size			$P < 0.88$		
Differentiation			$P < 0.33$		
Lymph node status			$P < 0.06^*$		
Margins			$P < 0.87$		
Adjuvant therapy			$P < 0.13^*$		

*These parameters were further included in multivariate analysis.
Pathologic data are available only for patients who underwent resection of tumor.

TABLE 3
Univariate Survival Analysis of Parameters Measured by ^{18}F-FDG PET

Variable	All patients ($n = 71$)	Localized			Metastatic ($n = 44$)
		All ($n = 27$)	Resected ($n = 11$)	Nonresectable ($n = 16$)	
SUV2	$P < 0.075$*	$P < 0.1275$	$P < 0.06$*	$P < 0.99$	$P < 0.37$
SUV1	$P < 0.11$*	$P < 0.24$	$P < 0.09$*	$P < 0.97$	$P < 0.33$
VB	$P < 0.06$*	$P < 0.16$*	$P < 0.15$*	$P < 0.44$	$P < 0.14$*
K_1	$P < 0.14$*	$P < 0.007$*	$P < 0.09$*	$P < 0.39$	$P < 0.17$*
k_2	$P < 0.289$	$P < 0.29$	$P < 0.076$*	$P < 0.799$	$P < 0.026$*
k_3	$P < 0.159$*	$P < 0.029$*	$P < 0.41$	$P < 0.35$	$P < 0.013$*
k_4	$P < 0.32$	$P < 0.32$	$P < 0.212$	$P < 0.32$	$P < 0.43$
K_1/k_2	$P < 0.77$	$P < 0.77$	$P < 0.977$	$P < 0.977$	$P < 0.43$
k_3/k_4	$P < 0.4$	$P < 0.0.4$	$P < 0.84$	$P < 0.54$	$P < 0.54$
^{18}F-FDG INF	$P < 0.0118$*	$P < 0.009$*	$P < 0.024$*	$P < 0.012$*	$P < 0.14$*
FD	$P < 0.102$*	$P < 0.102$*	$P < 0.183$*	$P < 0.08$*	$P < 0.8$

*These parameters were further included in multivariate analysis.

Total Group of Patients with PC

The total group of patients included 27 patients with localized PC (resected in 11 patients and locally advanced and nonresectable in 16 patients) and 44 patients with metastatic disease. There were no significant statistical differences between kinetic variables, equally distributed in localized and metastatic disease. Univariate analysis parameters related to OS were stage of disease, VB, K_1, k_3, FD, ^{18}F-FDG INF, SUV$_1$, and SUV$_2$. Prognostic factors for OS significant at multivariate analysis were stage of disease, VB, K_1, and ^{18}F-FDG INF. A high ^{18}F-FDG INF and K_1 with low VB were related to a short median OS of 3 mo, whereas a low ^{18}F-FDG INF and K_1 with high VB were related to a prolonged median OS of 14 mo ($P < 0.021$). Patients with other combinations of these 3 parameters had an intermediate prognosis, with a median OS of 6 mo (Fig. 4).

DISCUSSION

The present study aimed to assess quantitative ^{18}F-FDG PET kinetics as indices of tumor aggressiveness and predictors of outcome in patients with PC, a clinically heterogeneous malignancy.

Elevated glucose consumption plays an essential role in carcinogenesis and cancer progression (15–17). ^{18}F-FDG is an indicator of enhanced glycolysis in malignant tissues. The intensity of ^{18}F-FDG uptake cannot always accurately define the metabolic activity of tumor cells because non-phosphorylated intravascular and interstitial radiotracer can contribute to the overall intratumoral uptake. Therefore, visual assessment that does not always correlate with the tumor glucose metabolic rate was not used in the current study. Furthermore, confounding factors such as length of the uptake period after injection, lesion size, blood glucose levels, and insulin levels can influence semiquantitative ^{18}F-FDG uptake measurements (4).

The kinetic model used in the present study discriminates and further associates between molecular tumor patterns and parameters of ^{18}F-FDG kinetics. This model is based on the concept of 2 compartments containing ^{18}F-FDG, linked by kinetic processes that provide an exchange of ^{18}F-FDG and rate constants proportional to the rate of ^{18}F-FDG exchange between compartments: K_1 and k_2 define transmembrane transport of ^{18}F-FDG in both directions, and k_3 and k_4 define intracellular ^{18}F-FDG phosphorylation and dephosphorylation. The ^{18}F-FDG INF is calculated using the rate constants. The model also uses the VB of the target volume, because ^{18}F-FDG uptake is modulated by the fractional blood volume in the tumor. Additionally, a noncompartment model

TABLE 4
Cox Multivariate Survival Analysis of Significant Clinicopathologic and Kinetic ^{18}F-FDG PET Variables

Variable	All patients ($n = 71$)	Localized			Metastatic ($n = 44$)
		All ($n = 27$)	Resected ($n = 11$)	Nonresectable ($n = 16$)	
Stage	$P < 0.00035$				
^{18}F-FDG INF	$P < 0.0084$	$P < 0.0092$	$P < 0.0459$	$P < 0.0161$	
VB	$P < 0.030$				$P < 0.0432$
K_1	$P < 0.024$				$P < 0.031$
Tumor location				$P < 0.0189$	
k_3					$P < 0.009$

FIGURE 1. OS curves for patients with localized PC with high and low ^{18}F-FDG INF.

calculates the time–activity curve FD, which helps to quantify heterogeneity. Different expressions of these factors resulted in different ^{18}F-FDG accumulation profiles in benign versus malignant lesions and in low grade versus more aggressive tumors (7,9,10,18,19).

In primary and recurrent soft-tissue sarcoma, ^{18}F-FDG kinetic parameters improved the low specificity of visual analysis of PET, discriminating grades I and III tumors with a positive predictive value above 80% (18). The comparison of kinetic parameters at baseline and after 1–2 chemotherapy cycles predicted the outcome of chemotherapy for advanced sarcoma early (9,19). The combination of kinetic parameters measured before chemotherapy (k_3, k_4, VB, and FD) and after the fourth cycle (K_1, k_4, and VB) identified short- and long-term survivors with metastatic colorectal cancer (7). In multiple myeloma, k_3 and FD before and after 1 cycle of anthracycline-based chemotherapy predicted progression-free survival, high baseline k_3 being an indicator of worse outcome (10). These results demonstrate that the use of parametric images and quantitative parameters of tracer kinetics add a new dimension to ^{18}F-FDG PET/CT (20).

The relationship between ^{18}F-FDG activity and prognosis in PC has been previously analyzed using ^{18}F-FDG SUV measurements. Pretreatment-measured SUV significantly predicted OS in 55 patients with locally advanced PC receiving stereotactic body radiotherapy and gemcitabine-based chemotherapy (21). In 24 patients with advanced PC under chemotherapy, a high SUV predicted shorter OS (22). In both studies, SUV was a significant, independent factor for OS by multivariate analysis (21,22). In 56 patients with PC before resection, a high SUV was a risk factor for early postoperative recurrence (23). In the present study on univariate analysis, SUV_1 and SUV_2 were predictors of survival in all patients and in the subgroup with localized PC. However, these parameters were not significant for survival by multivariate analysis, probably because of the highly predictive significance of ^{18}F-FDG INF for OS.

In this study, kinetic ^{18}F-FDG parameters before therapy were analyzed as predictors of the clinical behavior of PC. The most important single parameter correlating with clinical outcome of localized PC was ^{18}F-FDG INF. High values predicted the same short median OS in patients with localized PC, whether resected or not (5 and 6 mo, respectively). Patients with a low ^{18}F-FDG INF fared significantly better and had a prolonged median OS in both subgroups (15 and 19 mo, respectively). ^{18}F-FDG INF, generated by a 2-tissue-compartment model from the transport and phosphorylation constant (K_1, k_2, and k_3), indicates the net tracer influx rate constant, provides an accurate estimate of tumor glucose consumption and metabolism, and thus reflects tumor aggressiveness and progression. In the present study, ^{18}F-FDG INF provides significant prognostic information on localized PC, which, if confirmed in further large-scale studies, might bring about questions on the rationale of performing pancreatectomy in a subgroup of patients with clinically resectable but aggressive disease, as well as possibly affecting the therapeutic strategy in patients with locally advanced, nonresectable disease.

Kinetic ^{18}F-FDG transport parameters (K_1, k_2) and the vascular fraction of tumor (VB) were significant factors for survival in metastatic PC. Stage was the most significant variable for OS in the whole study group, together with ^{18}F-FDG INF, K_1, and VB. However, grouping of the 3 significant kinetic parameters showed that a high ^{18}F-FDG INF and K_1 with low VB were related to a short OS (median, 3

FIGURE 2. Overall survival curves for patients with resected and nonresectable PC with high and low ^{18}F-FDG INF. P value displayed is calculated on all curves from log-rank analysis. non-res = nonresectable; res = resectable.

FIGURE 3 Examples of relationship between OS and ^{18}F-FDG tumor uptake kinetic curves used for calculation of ^{18}F-FDG INF. Blue curve = patient with OS of 19 mo and ^{18}F-FDG INF of 0.015; red curve = patient with OS of 4 mo and ^{18}F-FDG INF of 0.043.

FIGURE 4. OS curves for whole study group of patients with PC classified by combination of high and low significant VB, K_1, and ^{18}F-FDG INF values.

mo), whereas a low ^{18}F-FDG INF and K_1 with high VB were indicators of a longer OS (median, 14 mo), irrespective of stage. These results are in accordance with the previously reported poor prognosis in PC with increased metabolic activity and decreased blood flow (*24*). A perfusion/metabolism mismatch—that is, low tumor blood flow and high ^{18}F-FDG uptake—has been described in a variety of tumors and is associated with adverse tumor biology (*25*). A high metabolic rate and/or blood flow at baseline, calculated using dynamic PET, was more frequent in more aggressive triple-negative locally advanced breast cancer (*26*) and was associated with a poor response to neoadjuvant chemotherapy (*27*).

The present study is limited by the relatively small number of patients in the different subgroups and the nonuniform treatment strategies. However, the present results demonstrate the presence of a previously unknown relationship between kinetic ^{18}F-FDG parameters and the clinical course of disease that can have significant management consequences in patients with PC. Quantitative PET analysis is a cumbersome technique with value demonstrated mainly in a research setting. After the validation of its diagnostic and predictive value, it is to be expected that the acquisition protocol and software will be simplified for future clinical use.

CONCLUSION

Tumor aggressiveness and survival in patients with PC can be predicted by kinetic ^{18}F-FDG uptake parameters generated by dynamic PET studies performed at diagnosis, before the initiation of treatment. ^{18}F-FDG INF was found to be the single statistically significant variable for OS in patients with localized disease, whether nonresectable or after surgery. Survival of all patients, regardless of the stage of disease, was related to the ^{18}F-FDG INF, K_1, and VB kinetic variables. On the basis of the current preliminary results, absolute quantitation of ^{18}F-FDG kinetics represents a potential tool for noninvasive characterization of tumor aggressiveness and may, in the future, be integrated into a prognostic score for individualized treatment tai-

loring in patients with newly diagnosed cancer of the pancreas—most importantly, in those with localized disease. Treatment can be intensified in patients with a high ^{18}F-FDG INF, whether resectable or not, while using a less aggressive therapeutic approach in patients with a low ^{18}F-FDG INF and conservative treatment without initial surgery in patients with borderline resectable tumor and low ^{18}F-FDG INF.

DISCLOSURE

REFERENCES

1. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Statistics. Available at: http://seer.cancer.gov/statistics. Accessed November 9, 2012.
2. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. *Ann Surg Oncol.* 2010;17:981–990.
3. Goulart BH, Clark JW, Lauwers GY, et al. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: A retrospective analysis. *J Hematol Oncol.* 2009;2:13.
4. Castell F, Cook GJR. Quantitative techniques in ^{18}FDG PET scanning in oncology. *Br J Cancer.* 2008;98:1597–1601.
5. Strauss LG, Dimitrakopoulou-Strauss A, Kontaxakis G, et al. PET data processing and image evaluation on PC systems [abstract]. *J Nucl Med.* 1999;40(suppl):292P.
6. Strauss LG, Klippel S, Pan L, et al. Assessment of quantitative FDG PET data in primary colorectal tumors: Which parameters are important with respect to tumor detection? *Eur J Nucl Med Mol Imaging.* 2007;34:868–877.
7. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of ^{18}F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. *J Nucl Med.* 2004;45:1480–1487.
8. Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach MH, Strauss LG. Quantitative, dynamic ^{18}F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. *Hell J Nucl Med.* 2009;12:223–228.
9. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. *Eur J Nucl Med Mol Imaging.* 2010;37:1481–1489.
10. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. *Clin Nucl Med.* 2009;34:576–584.
11. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of short-term survival in patients with advanced non-small cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-Dglucose-positron emission tomography: a feasibility study. *Mol Imaging Biol.* 2007;9:308–317.
12. Miyazawa H, Osmont A, Petit-Taboue MC, et al. Determination of ^{18}F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. *J Neurosci Methods.* 1993;50:263–272.
13. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. *J Nucl Med.* 1991;32:1432–1438.
14. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajezyk K, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. *World J Nucl Med.* 2003;2:306–313.

15. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. *J Nucl Med.* 2008;49(suppl2):24S–42S.

16. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000;100:57–70.

17. Jadvar H, Alavi A, Gambhir SS. ^{18}F-FDG uptake in lung, breast and colon cancer: molecular biology correlates and disease characterization. *J Nucl Med.* 2009;50:1820–1827.

18. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic PET ^{18}F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. *J Nucl Med.* 2001; 42:713–720.

19. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Impact of dynamic ^{18}F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. *J Nucl Med.* 2010;51:551–558.

20. Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Parametric imaging: a promising approach for the evaluation of dynamic PET-^{18}F-FDG studies: the DKFZ experience. *Hell J Nucl Med.* 2010;13:18–22.

21. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. *Int J Radiat Oncol Biol Phys.* 2010;77:1420–1425.

22. Ueno M, Ohkawa S, Miyakawa K, et al. Usefulness of FDG-PET in predicting the prognosis of advanced pancreatic carcinoma with chemotherapy [abstract]. *Proc Am SocClinOncol.* 2006;24:18s.

23. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. *Int J Clin Oncol.* 2011; 16:39–44.

24. Komar G, Kauhanen S, Liukko K, et al. Decreased blood low with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. *Clin Cancer Res.* 2009;15:5511–5517.

25. Mankoff DA, Dunnwald LK, Partridge SC, Specht LM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. *Clin Cancer Res.* 2009;15: 5294–5296.

26. Specht JM, Kurland BF, Montgomory SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. *Clin Cancer Res.* 2010;16:2803–2810.

27. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. *J Clin Oncol.* 2008;26:4449–4457.